All In Biotech

Drug Trial Radar · NCT00000419

Safety of Estrogens in Lupus: Hormone Replacement Therapy

Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA): Hormone Replacement Therapy

Last checked: Nov 20, 2026Latest source record: May 3, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

350

Actual

Start

Apr 1996

Primary completion

Not stated

Study completion Aug 2002

Sponsor

Lead sponsor
NYU Langone HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Office of Research on Women's Health (ORWH)
First posted
Nov 4, 1999

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
Double
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA) is a study to test whether postmenopausal women with systemic lupus erythematosus (SLE, or lupus) can safely use the hormone estrogen. In this part of the study, we will look at the effects of estrogen replacement therapy on the activity and severity of disease in women with SLE.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • Premarin and ProveraDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • UAB Medical Center

    Birmingham, Alabama

  • UCLA Medical Center, Dept. of Rheumatology

    Los Angeles, California

  • University of Chicago Pritzker School of Medicine

    Chicago, Illinois

  • Louisiana School of Medicine

    Shreveport, Louisiana

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Univ. of Michigan Med. Ctr., Rheumatology Div.

    Ann Arbor, Michigan

  • Hospital for Joint Diseases

    New York, New York

  • Hospital for Special Surgery

    New York, New York

  • Albert Einstein College of Medicine, Jacoby Hospital, Dept. of Rheumatology

    The Bronx, New York

  • UNC Medical Center, Dept. of Rheumatology

    Chapel Hill, North Carolina

  • Oklahoma Medical Research Foundation

    Oklahoma City, Oklahoma

  • Univ. of Pennsylvania Medical Center

    Philadelphia, Pennsylvania

  • Univ. of Pittsburgh, Dept. of Rheumatology

    Pittsburgh, Pennsylvania

  • University of Texas Health Sciences Center

    Houston, Texas

  • Medical College of Virginia, Ambulatory Care Center

    Richmond, Virginia

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.